Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

The new players in obesity drug development

Apart from Novo Nordisk and Eli Lilly, numerous other players have an attractive anti-obesity drug pipeline, and new ones are constantly entering this highly dynamic market. Dr. Lukas Leu and Dr. Christian Lach, Portfolio Managers of the Bellevue Obesity Solutions Fund, explain which companies are particularly promising.
08.07.2024 - Christian Lach, Lukas Leu

These investment strategies might interest you